tradingkey.logo
tradingkey.logo
Search

Neuropace Inc

NPCE
Add to Watchlist
16.140USD
+0.370+2.35%
Close 07/02, 13:00ETQuotes delayed by 15 min
541.90MMarket Cap
LossP/E TTM

Neuropace Inc

16.140
+0.370+2.35%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+2.35%

5 Days

-2.00%

1 Month

-1.10%

6 Months

+6.39%

Year to Date

+4.53%

1 Year

+55.34%

Key Figures
15.890Open
16.360High
117.36KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.35%Turnover Ratio
15.770Prev. Close
15.685Low
1.30MTurnover
LossP/E Static
28.47P/B
0.00%Div Yield TTM
-20.63%ROA
19.60052wk High
0.70Volume Ratio
-27.14MNet Profit
33.57MShares
-0.6451EPS TTM
1.91Beta
-111.38%ROE
7.56352wk Low
4.28%Amplitude
81.78%Gross Margin
541.90MMarket Cap
-1.07Reward/Risk
3.14%Risk Rate

TradingKey Stock Score of Neuropace Inc

Currency: USD Updated: 2026-07-02

Key Insights

Neuropace Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 62 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuropace Inc's Score

Industry at a Glance

Industry Ranking
62 / 204
Overall Ranking
155 / 4565
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Neuropace Inc Highlights

StrengthsRisks
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.83% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 99.99M.
Undervalued
The company’s latest PE is -25.02, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.54M shares, decreasing 11.02% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 117.23K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
20.000
Target Price
+26.82%
Upside Space

Neuropace Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Neuropace Inc Info

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Ticker SymbolNPCE
CompanyNeuropace Inc
CEOBecker (Joel D)
Websitehttps://www.neuropace.com/

FAQs

What is the current price of Neuropace Inc (NPCE)?

The current price of Neuropace Inc (NPCE) is 16.14.

What is the symbol of Neuropace Inc?

The ticker symbol of Neuropace Inc is NPCE.

What is the 52-week high of Neuropace Inc?

The 52-week high of Neuropace Inc is 19.60.

What is the 52-week low of Neuropace Inc?

The 52-week low of Neuropace Inc is 7.56.

What is the market capitalization of Neuropace Inc?

The market capitalization of Neuropace Inc is 541.90M.

Is Neuropace Inc (NPCE) currently rated as Buy, Hold, or Sell?

According to analysts, Neuropace Inc (NPCE) has an overall rating of Buy, with a price target of 20.00.

What is the Earnings Per Share (EPS TTM) of Neuropace Inc (NPCE)?

The Earnings Per Share (EPS TTM) of Neuropace Inc (NPCE) is -0.66.